Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01268280 · ClinicalTrials.gov registry record · Phase 2
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
A Phase 2 study, sponsored by Cytokinetics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT01268280 is a Phase 2 study that was terminated before completion, run by Cytokinetics. The registered enrollment target is 32 participants.
The verdict
NCT01268280, a Phase 2 study, was terminated before completion, sponsored by Cytokinetics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The primary objective of this early-stage clinical study is to demonstrate an effect of single doses of CK-2017357 on measures of skeletal muscle function and fatigability in patients with generalized myasthenia gravis (MG).
Interventions
- DRUG Placebo
- DRUG 500 mg CK-2017357
- DRUG 250 mg CK-2017357
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2010-12 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01268280
The ClinicalTrials.gov registry entry for NCT01268280 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cytokinetics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01268280 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01268280 about?
NCT01268280 is a clinical study titled "Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis". The primary objective of this early-stage clinical study is to demonstrate an effect of single doses of CK-2017357 on measures of skeletal muscle function and fatigability in patients with generalized myasthenia gravis (MG).
What is the current status of trial NCT01268280?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2010-12. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01268280?
The interventions under investigation include: Placebo (DRUG), 500 mg CK-2017357 (DRUG), 250 mg CK-2017357 (DRUG).
Who is sponsoring clinical trial NCT01268280?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.